JAMA Internal Medicine today published a trio of studies on use of the immunosuppressive drug tocilizumab in COVID-19 patients with pneumonia, one of them a large US observational study that suggested some promise and two randomized clinical trials from Italy and France that found no benefit.Equivocal results in ICU patientsThe first study involved 3,924 adult COVID-19 patients admitted to intensive care units (ICUs) at 68 hospitals in the United States from Mar 4 to May 10.Of the 433 patients who received tocilizumab in the first 2 days of their ICU stay, 125 (28.9%) died, compared with the 1,419 of 3,491 (40.6%) who received usual care.